Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) has announced it is filing a Form 4B to obtain price protection for the closing of the third tranche of its previously disclosed non-brokered private placement, originally announced on June 17, 2026, targeting total gross proceeds of $1,000,000. Each unit consists of one common share and one-half of one common share purchase warrant exercisable at CDN$0.12 per share for 24 months from the closing date of the third tranche. The announcement is subject to final acceptance by the TSX Venture Exchange, making regulatory clearance a key milestone for investors to monitor.

Key Points

  • Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is an autologous stem cell therapy platform company based in Calgary, Alberta.
  • The company is filing a Form 4B to secure price protection for the third tranche of its non-brokered private placement targeting $1,000,000 in gross proceeds.
  • Warrants are exercisable at CDN$0.12 per share for 24 months, with an acceleration provision triggered if the volume-weighted average price reaches CDN$0.15 or higher over 10 consecutive trading days.
  • Investors should watch for final Exchange acceptance and the formal closing of the third tranche.

Warrant Terms and Accelerated Expiry Provision for the Third Tranche

Each whole warrant issued under the offering entitles the holder to acquire one additional common share at CDN$0.12 for 24 months from the third tranche closing date. The release states that if the volume-weighted average trading price of Hemostemix common shares equals or exceeds CDN$0.15 over any 10 consecutive trading days — occurring after four months and one day from closing — the company may accelerate warrant expiry to 30 days following the issuance of a news release announcing the acceleration. This provision gives the company a mechanism to manage its capital structure if the share price strengthens.

Finder Fees and Finder Warrants Connected to the Third Tranche

In connection with the third tranche, the company disclosed it expects to pay eligible finders aggregate cash fees of approximately CDN$8,000 and has issued 80,000 finder warrants. Each finder warrant entitles the holder to purchase one common share at CDN$0.06 per share for a period of 24 months from the closing date of the second tranche. All securities issued remain subject to a statutory hold period of four months plus one day from the closing date, in accordance with applicable Canadian securities laws, along with any additional restrictions applicable in jurisdictions outside Canada.

How Hemostemix Plans to Deploy Offering Proceeds

The company states proceeds are expected to fund sales, marketing, patient acquisition, and physician education initiatives, as well as production and manufacturing expenses associated with ACP-01 treatments. Additional uses include regulatory and filing fees related to submissions to the Ministry of Health and Wellness of the Commonwealth of The Bahamas, and general working capital. Hemostemix describes itself as an autologous stem cell therapy company whose lead investigational therapy, VesCell™, is derived from a patient's own blood and targets diseases of ischemia.